Enzo forms bone growth products deal:
This article was originally published in Clinica
Executive Summary
Enzo Biochem has linked up with the University of Connecticut Health Center, at Farmington, to develop novel therapeutics to spur bone growth. The company's Enzo Therapeutics subsidiary has formed two agreements with the university concerning a technology that could provide a promising means of modulating cell development, cell differentiation and cell renewal pathways, including those of bone and haematopoeitic cells," said Dean Engelhardt, the Farmingdale, New York firm's executive vice-president. Products emanating from the technology could provide therapy for bone disorders, including bone loss, fractures, abnormalities, diseases and other applications.